9-Test substances and procedures

Characterisation of test substances (e.g. chemicals) is generally easier than characterisation of the test system (e.g. cells, tissues, organs, animals) to which they are applied, with some exceptions such as early candidate molecules in pharmaceutical research. As much information as possible should be provided to the animal facility.

Laboratory Maintenance Checklists from Mettler Toledo

General principles
For fish researchers

Characterisation of test substances (e.g. chemicals) is generally easier than characterisation of the test system (e.g. cells, tissues, organs, animals) to which they are applied, with some exceptions such as early candidate molecules in pharmaceutical research. As much information as possible should be provided to the animal facility. This may include:

  • the origin, purity, solubility and batch number of the substance
  • any necessary pre-treatment before administration to the animals, such as dilution or mixing with adjuvant
  • its likely palatability if given orally in feed or water (which may cause artefacts in observations of body weight)
  • storage conditions before use
  • routines for disposal of surplus material
  • health risks on human exposure, and the likely effects of substances that leak to, or are knowingly released into, the environment. Technical data sheets should always be provided if these are available.

Immunisation protocols should be refined to prevent unnecessary pain and suffering caused by the use of adjuvants (see the references below). 

When calculating the dose to be used, particularly if this is based upon human data, allometric scaling should be used, to take into account the large differences in metabolic rate between animals of different body mass.

Desirable characteristics of a dosing formulation and its preparation

Vehicles for animal studies

The OECD QSAR Toolbox

Guidance for dose selection in DART studies to refine and reduce animal use (NC3Rs, 2024)

Recommendations to accelerate the replacement of animal-derived antibodies (NC3Rs, 2024)

Clinical molecules: a library from AstraZeneca of clinic-ready molecules demonstrating target engagement and tolerability through Phase 2 research.

This page was updated on 06 March 2024

Did you find what you were looking for?

Yes, I found it! No, I did not!

Thanks for your feedback! Please note that we cannot reply to you unless you send us an email.

What are you looking for?

We value your feedback so we can improve the information on the page. Please add your email address if you would like a reply. Thank you in advance for your help.!

Please contact us by email if you have any questions.

Thanks for your feedback! Please note that we cannot reply to you unless you send us an email.



 

Abonnér på nyhetsbrevene fra Norecopa